Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

November 7, 2022

https://www.globenewswire.com/news-release/2022/11/07/2549613/0/en/Vaccitech-Provides-Update-on-Ongoing-VTP-300-Phase-1b-2a-Trial-Showing-Sustained-Reductions-of-HBsAg-in-Patients-with-Chronic-Hepatitis-B.html

VTP-300 induced sustained reductions of hepatitis B surface antigen in people with chronic hepatitis B during ongoing, fully enrolled Phase 1b/2a trial.

VTP-300 as a monotherapy and in combination with a single administration of low-dose nivolumab demonstrated no treatment-related serious adverse events and infrequent transient transaminitis, as of 28 September 2022.

Read more at globenewswire.com

Related news for (VACC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.